TTM
-$60.3M
YoY change
-29.6%
5Y CAGR
—
Peak year (FY2012)
-$12.1K
Cumulative operating income
-$689M
Operating Income history chart for Relmada Therapeutics (RLMD) from 2017 to 2025
Latest: -$59.1M
Operating Income growth chart for Relmada Therapeutics (RLMD) from 2017 to 2025
Latest: -29.6%
Operating Income history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| FY2025 | -$59.1M | -29.6% | +$24.8M | ||
| FY2024 | -$83.9M | -19.1% | +$19.8M | ||
| FY2023 | -$104M | -35.7% | +$57.5M | ||
| FY2022 | -$161M | +28.3% | -$35.5M | ||
| FY2021 | -$126M | +106.6% | -$64.9M | ||
| FY2020 | -$60.8M | +302.7% | -$45.7M | ||
| FY2019 | -$15.1M | +18.7% | -$2.38M | ||
| FY2018 | -$12.7M | +84.0% | -$5.81M | ||
| FY2017 | -$6.92M | -4.2% | +$302K | ||
| FY2016 | -$7.22M | -55.5% | +$9M | ||
| FY2015 | -$16.2M | -5.2% | +$883K | ||
| FY2014 | -$17.1M | +37885.1% | -$17.1M | ||
| FY2013 | -$45K | +273.5% | -$33K | ||
| FY2012 | -$12.1K | — | — |
- FY2025-$59.1M-29.6%
- FY2024-$83.9M-19.1%
- FY2023-$104M-35.7%
- FY2022-$161M+28.3%
- FY2021-$126M+106.6%
- FY2020-$60.8M+302.7%
- FY2019-$15.1M+18.7%
- FY2018-$12.7M+84.0%
- FY2017-$6.92M-4.2%
- FY2016-$7.22M-55.5%
- FY2015-$16.2M-5.2%
- FY2014-$17.1M+37885.1%
- FY2013-$45K+273.5%
- FY2012-$12.1K—
Operating Income values are taken from Relmada Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's current operating income (TTM) is -$60.3M. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Relmada Therapeutics (RLMD) reported operating income of -$59.1M – declined 29.6% year-over-year.
2012 marks the peak operating income at -$12.1K, with the historical low of -$161M recorded in 2022.
Relmada Therapeutics Operating Income by Year
Relmada Therapeutics Operating Income 2025: -$59.1M
In 2025, Relmada Therapeutics reported operating income of -$59.1M, declined 29.6% below 2024.
Relmada Therapeutics Operating Income 2024: -$83.9M
Relmada Therapeutics operating income in 2024 was -$83.9M, declined 19.1% below 2023.
Relmada Therapeutics Operating Income 2023: -$104M
2023's operating income for Relmada Therapeutics came in at -$104M, plunged 35.7% below 2022.
Relmada Therapeutics Operating Income 2022: -$161M
Relmada Therapeutics posted operating income of -$161M in 2022, grew 28.3% from 2021. This figure represents the lowest annual value in the available history.
Relmada Therapeutics Operating Income 2021: -$126M
Relmada Therapeutics operating income in 2021 was -$126M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Operating Income
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest operating income
| $29.7B | |
| $25.6B | |
| $23.5B | |
| $20.1B | |
| $19.9B | |
| $19B | |
| $10.7B | |
| $8.11B |
- $29.7B
- $25.6B
- $23.5B
- $20.1B
- $19.9B
- $10.7B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.